Therapies on the horizon for cholesterol reduction

Clinical Cardiology

Volumn 24, Issue 8 SUPPL., 2001, Pages

  Brown, W V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Avasimibe; Bile transport inhibitors; Ezetimibe; NK 104; Rosuvastatin

Indexed keywords

AVASIMIBE; COLESEVELAM; EZETIMIBE; PITAVASTATIN; ROSUVASTATIN; STATIN; UNCLASSIFIED DRUG;

ARTERY WALL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; MACROPHAGE ACTIVATION; RECEPTOR UPREGULATION; REVIEW; RISK BENEFIT ANALYSIS;

EID: 17344383539     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960241506     Document Type: Review

References (23)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
2. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
3. Statin therapy and reductions in low-density lipoprotien cholesterol: Initial clinical data on the potent new statin rosuvastatin
4. ZD4522 is superior to atorvastatin in decreasing low-density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia
5. ZD4522 is superior to pravastatin and simvastatin in reducing low-density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low-density lipoprotein cholesterol guidelines
6. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia
7. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs
8. The Lipid Research Clinics Coronary Primary Prevention Trial: Design, results, and implications
9. Review of clinical trials: Proving the lipid hypothesis
10. Colesevelam hydrochloride: A non-absorbed, polymeric cholesterol-lowering agent
11. Colesevelam hydrochloride (Cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects
12. +/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits
13. A target for cholesterol absorption inhibitors in the enterocyte brush border membrane
14. Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter
15. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4- hydroxyphenyl)-2-azetidinone (SCH 58235): A designed, potent, orally active inhibitor of cholesterol absorption
16. Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesterolemic subjects: Resuits of a dose-response study
17. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by SCH 58235: Pooled analysis of two phase II studies
18. Recombinant acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) purified to essential homogeneity utilizes cholesterol in mixed micelles or in vesicles in a highly cooperative manner
19. Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages
20. ACAT-2 a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization
21. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits
22. Inhibitory effect of TS-962 on the formation of early atherosclerotic lesions in high fat-fed hyperlipidemic hamsters